Literature DB >> 25829527

Prostate cancer survivorship care guidelines: American Society of Clinical Oncology practice guideline endorsement.

Matthew J Resnick1, Christina Lacchetti2, David F Penson1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25829527     DOI： 10.1200/JOP.2015.004606

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  11 in total

1.  Has the Quality of Patient-Provider Communication About Survivorship Care Improved?

Authors:  Ashish Rai; Neetu Chawla; Xuesong Han; Sun Hee Rim; Tenbroeck Smith; Janet de Moor; Karen R Yabroff
Journal:  J Oncol Pract       Date:  2019-07-02       Impact factor: 3.840

2.  Going Beyond Being Lost in Transition: A Decade of Progress in Cancer Survivorship.

Authors:  Larissa Nekhlyudov; Patricia A Ganz; Neeraj K Arora; Julia H Rowland
Journal:  J Clin Oncol       Date:  2017-04-24       Impact factor: 44.544

3.  Primary Care Provider Involvement in Thyroid Cancer Survivorship Care.

Authors:  Archana Radhakrishnan; David Reyes-Gastelum; Brittany Gay; Sarah T Hawley; Ann S Hamilton; Kevin C Ward; Lauren P Wallner; Megan R Haymart
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

4.  NCCN Guidelines Insights: Survivorship, Version 2.2019.

Authors:  Tara Sanft; Crystal S Denlinger; Saro Armenian; K Scott Baker; Gregory Broderick; Wendy Demark-Wahnefried; Debra L Friedman; Mindy Goldman; Melissa Hudson; Nazanin Khakpour; Divya Koura; Robin M Lally; Terry S Langbaum; Allison L McDonough; Michelle Melisko; Kathi Mooney; Halle C F Moore; Javid J Moslehi; Tracey O'Connor; Linda Overholser; Electra D Paskett; Lindsay Peterson; William Pirl; M Alma Rodriguez; Kathryn J Ruddy; Sophia Smith; Karen L Syrjala; Amye Tevaarwerk; Susan G Urba; Phyllis Zee; Nicole R McMillian; Deborah A Freedman-Cass
Journal:  J Natl Compr Canc Netw       Date:  2019-07-01       Impact factor: 11.908

5.  Health information needs and preferences in relation to survivorship care plans of long-term cancer survivors in the American Cancer Society's Study of Cancer Survivors-I.

Authors:  Mary Playdon; Leah M Ferrucci; Ruth McCorkle; Kevin D Stein; Rachel Cannady; Tara Sanft; Brenda Cartmel
Journal:  J Cancer Surviv       Date:  2016-01-07       Impact factor: 4.442

6.  Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies.

Authors:  Aaron Spitz; Marc Gittelman; Lawrence I Karsh; Sanja Dragnic; Ahmed M Soliman; Aditya Lele; Damian Gruca; Michael Norton
Journal:  Res Rep Urol       Date:  2016-08-23

7.  Implementing physical activity programs for patients with cancer in current practice: patients' experienced barriers and facilitators.

Authors:  Charlotte IJsbrandy; Rosella P M G Hermens; Laura W M Boerboom; Winald R Gerritsen; Wim H van Harten; Petronella B Ottevanger
Journal:  J Cancer Surviv       Date:  2019-07-25       Impact factor: 4.442

8.  Cancer Survivorship Care: Person Centered Care in a Multidisciplinary Shared Care Model.

Authors:  Jacqueline J Loonen; Nicole Ma Blijlevens; Judith Prins; Desiree Js Dona; Jaap Den Hartogh; Theo Senden; Eline van Dulmen-Den Broeder; Koos van der Velden; Rosella Pmg Hermens
Journal:  Int J Integr Care       Date:  2018-01-16       Impact factor: 5.120

9.  Targeting Hsp27/eIF4E interaction with phenazine compound: a promising alternative for castration-resistant prostate cancer treatment.

Authors:  Hajer Ziouziou; Claudia Andrieu; Erik Laurini; Sara Karaki; Maurizio Fermeglia; Ridha Oueslati; David Taieb; Michel Camplo; Olivier Siri; Sabrina Pricl; Maria Katsogiannou; Palma Rocchi
Journal:  Oncotarget       Date:  2017-08-24

10.  Determinants of adherence to physical cancer rehabilitation guidelines among cancer patients and cancer centers: a cross-sectional observational study.

Authors:  Charlotte IJsbrandy; Petronella B Ottevanger; Winald R Gerritsen; Wim H van Harten; Rosella P M G Hermens
Journal:  J Cancer Surviv       Date:  2020-09-28       Impact factor: 4.442
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.